Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission

Related Clinical Trial
Study of Colchicine Resistance in Familial Mediterranean Fever Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever Central Sensitization in Familial Mediterranean Fever (FMF) Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine Effects of Online Aerobic Exercise Training and Physical Activity Counseling in Juvenile Familial Mediterranean Fever Characterization of a Functional Test for Mediterranean Family Fever Screening – 2 Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis Heat Intolerance in the Group of FMF Patients Magnetic Resonance (MR) Spectroscopy In Familial Mediterranean Fever (FMF) Patients Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission Tocilizumab for the Treatment of Familial Mediterranean Fever Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation The Effect of Probiotics on Response to Therapy and on Adverse Effect in Patients Treated With Colchicine for Familial Mediterranean Fever. A Diagnostic Test for Familial Mediterranean Fever Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever Rilonacept for Treatment of Familial Mediterranean Fever (FMF)

Brief Title

Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission

Official Title

Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission

Brief Summary

      Familial Mediterranean fever (FMF) is a genetic disease, caused by mutations in the FMF gene,
      entitled MEFV. The disease is characterized by painful attacks of inflammation in sites lined
      by serous membranes (e.g. abdominal pain caused by inflammation of the peritoneum, a serous
      membrane surrounding all internal organs within the abdomen). Continuous colchicine treatment
      prevents attacks in most patients. The pathogenesis of the disease, what leads to the attacks
      and how colchicine helps, are questions not yet resolved. Elucidating the role of the
      inflammatory proteins is an important step towards the understanding of these questions. To
      date only small numbers of cytokines and inflammatory proteins have been studied
      individually. We propose to study a large number of these proteins in the RNA and protein
      levels addressing the interaction between them and the effect of colchicine on their
      expression.

      Blood samples will be drawn from consenting patients in remission, during attacks, under and
      without colchicine treatment. (20 patients in each category).Twenty healthy volunteers will
      donate control blood samples for the study. RNA will be produced from the neutrophils, and
      cytokines and various proteins' RNA expression will be determined. Major expressed proteins
      will be measured in the same samples and the results will be analyzed with regard to the
      activity of the disease, MEFV mutations and colchicine treatment status. The information
      obtained by the study may allow us to determine the sequence of events associated with FMF
      attack development, and perhaps take us one step further in the understanding of the
      pathogenesis of the disease.
    

Detailed Description

      Familial Mediterranean fever (FMF) is a genetic disease, caused by mutations in the FMF gene,
      entitled MEFV. The disease is characterized by painful attacks of inflammation in sites lined
      by serous membranes (e.g. abdominal pain caused by inflammation of the peritoneum, a serous
      membrane surrounding all internal organs within the abdomen). Continuous colchicine treatment
      prevents attacks in most patients. The pathogenesis of the disease, what leads to the attacks
      and how colchicine helps, are questions not yet resolved. Elucidating the role of the
      inflammatory proteins is an important step towards the understanding of these questions. To
      date only small numbers of cytokines and inflammatory proteins have been studied
      individually. We propose to study a large number of these proteins in the RNA and protein
      levels addressing the interaction between them and the effect of colchicine on their
      expression.

      Blood samples will be drawn from consenting patients in remission, during attacks, under and
      without colchicine treatment. (20 patients in each category).Twenty healthy volunteers will
      donate control blood samples for the study. RNA will be produced from the neutrophils, and
      cytokines and various proteins' RNA expression will be determined. Major expressed proteins
      will be measured in the same samples and the results will be analyzed with regard to the
      activity of the disease, MEFV mutations and colchicine treatment status. The information
      obtained by the study may allow us to determine the sequence of events associated with FMF
      attack development, and perhaps take us one step further in the understanding of the
      pathogenesis of the disease.
    


Study Type

Observational




Condition

Familial Mediterranean Fever


Study Arms / Comparison Groups

 Group 1
Description:  FMF patients in remission

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

0

Start Date

August 2008

Completion Date

August 2016

Primary Completion Date

August 2010

Eligibility Criteria

        Inclusion Criteria:

          -  FMF patients, agreeing with diagnostic criteria, in attack or remission, under or
             without colchicine treatment.

          -  Age 18 or older

          -  Male or female

          -  all ethnic groups arriving for treatment or routine follow up appointment

          -  Written Consent to participate and donate blood for protein, RNA and DNA analyses.

        Exclusion Criteria:

          -  Younger than 18

          -  Patients that use anti inflammatory medications, other than colchicine

          -  Patients who in addition to FMF suffer from another acute infectious or inflammatory
             disease

          -  Patients who in addition to FMF suffer from another chronic infectious or inflammatory
             or autoimmune disease.

          -  Amyloidosis

          -  Pregnancy
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Avi Livneh, MD, , 

Location Countries

Israel

Location Countries

Israel

Administrative Informations


NCT ID

NCT00323440

Organization ID

SHEBA-06-4126-AL-CTIL


Responsible Party

Sponsor

Study Sponsor

Sheba Medical Center


Study Sponsor

Avi Livneh, MD, Principal Investigator, Sheba Medical Center


Verification Date

October 2017